Skip to content
10-Q

Quarterly Report

ENDONOVO THERAPEUTICS, INC. ENDV

0001493152-23-018538

← back to feed
Filed
May 22, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 19, 2023 281.64M sh
Shares Diluted Q1 2023 · Mar 31, 2023 1.74B sh
Shares Diluted Q1 2023 · Mar 31, 2022 79.01M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$173.16K
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$122.95K
Long Term Debt Q1 2023 · Mar 31, 2023 $6.9M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $10.94K
Cash And Equivalents Q1 2023 · Dec 31, 2022 $98
Stockholders Equity Q1 2023 · Mar 31, 2023 −$24.37M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$32.18M
Stockholders Equity Q1 2023 · Mar 31, 2022 −$18.04M
Stockholders Equity Q1 2023 · Dec 31, 2021 −$15.77M
Current Liabilities Q1 2023 · Mar 31, 2023 $25.49M
Current Liabilities Q1 2023 · Dec 31, 2022 $33.38M
Total Liabilities Q1 2023 · Mar 31, 2023 $25.57M
Total Liabilities Q1 2023 · Dec 31, 2022 $33.46M
Current Assets Q1 2023 · Mar 31, 2023 $95.17K
Current Assets Q1 2023 · Dec 31, 2022 $15.82K
Total Assets Q1 2023 · Mar 31, 2023 $1.2M
Total Assets Q1 2023 · Dec 31, 2022 $1.28M
Eps Diluted Q1 2023 · Mar 31, 2023 $0.00
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.03
Eps Basic Q1 2023 · Mar 31, 2023 $0.03
Eps Basic Q1 2023 · Mar 31, 2022 −$0.03
Net Income Q1 2023 · Mar 31, 2023 $7.23M
Net Income Q1 2023 · Mar 31, 2022 −$2.41M
Operating Income Q1 2023 · Mar 31, 2023 −$529.29K
Operating Income Q1 2023 · Mar 31, 2022 −$485.76K
Gross Profit Q1 2023 · Mar 31, 2023 $83.54K
Gross Profit Q1 2023 · Mar 31, 2022 $1.57K
Cost Of Revenue Q1 2023 · Mar 31, 2023 $4K
Cost Of Revenue Q1 2023 · Mar 31, 2022 $714
Revenue Q1 2023 · Mar 31, 2023 $87.54K
Revenue Q1 2023 · Mar 31, 2022 $2.28K